Given the biphasic nature of cannabinoid effects (where lower doses may be therapeutic while higher doses can lead to diminishing returns or adverse effects), the lack of a uniform dosing protocol presents a major confounding variable. Variability in bioavailability and metabolism can lead to inconsistent pain relief across studies, making direct comparisons difficult. It decreased mean emergency department visits in the past calendar year for patients who received marijuana as an adjunct to opioids in the treatment of non-cancer chronic pain compared to those who did not receive marijuana .
I’ve used the cream on my shoulders, but I haven’t seen any help from it either. ” 73 years (female I would choke on it for the first week), but the past week I’ve been able to use it. ” 58 years, female It feels good sometimes, but I don’t like the side effects or being unable to work. ” 49 years, male Not so much with pain or mental issues. ” 56 years — female It has been absolutely fantastic as I have found the perfect mix for the right time of day. It medical cannabis takes the edge off plenty where I feel human again. ” 56 years, female
Moderate certainty evidence also suggests that the use of cannabis for medical use versus opioids resulted in fewer discontinuations due to adverse events. The magnitude of effects versus placebo for cannabis for medical use or opioids was modest — with the modelled RD for achieving the MID for pain, physical functioning and sleep ranging from 5% to 15%. Moderate and high certainty evidence showed that, compared with placebo, opioids and cannabis for medical use, respectively, probably result in higher discontinuations compared with placebo (modelled RD for achieving the MID for opioids vs placebo, 10%, 95% CrI 8% to 12%; cannabis for medical use vs placebo, 4%, 95% CrI 1% to 7%) (table 2, online supplemental eFigure 14–17). Moderate certainty evidence shows that in non-enriched studies — discontinuations due to adverse events are probably less for cannabis for medical use versus opioids (OR 0.55, 95% CrI 0.36 to 0.83) (table 2).
Results:
Unlike opioids, it doesn’t come with the same concerns around overdose and addiction. New findings suggest it can be effective for low back pain, on par with opioids https://usaweed.org/2025/10/14/flavor-profiles-define-your-cannabis-journey/ . The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday The IRB waived additional informed consent, and all procedures adhered to applicable privacy regulations.
Cannabinoids and cannabis.
Additional studies on the use of cannabinoids for headache disorders are needed, as all remaining evidence is derived from clinical experience and case reports. A mean pain intensity rating on a numeric scale decreased from 8.7 to 4.9 in patients treated with THC, demonstrating both a reduction in opioid doses and maximum pain intensity. Variability in individual responses was highlighted by Jensen et al. (who noticed inconsistent benefits from THC that provided relief to some patients), but not to all. A significant improvement in pain was shown in a randomized control trial conducted by Skrabek et al., where nabilone, a synthetic analog of THC taken orally, resulted in an average reduction of −2.04 in visual analog scale pain scores compared to placebo.
A few participants in the study reported side effects — including impaired work performance, stomach issues, an unwanted high, and choking while vaping. According to participant feedback (a potential additional benefit linked to medical cannabis usage is improved physical mobility), likely due to alleviated pain symptoms. The qualitative findings indicated observed enhancements in both physical health and functionality. These results are consistent with earlier meta-analyses that suggest medical cannabis treatment could lead to better pain management (Whiting et al., 2015; Wong et al., 2020; Yanes et al., 2019). Overall — participants shared their experiences of experimenting with various strains of medical cannabis and modifying the CBD to THC ratio for optimized treatment effects. I believe that it makes me feel more fatigued during the day, indicating that progress is still ongoing.
In conclusion — studies indicate, though with low-quality evidence, that cannabinoids might provide an opioid-sparing effect for patients using opioids for pain management. The high-certainty evidence derived from the randomized trials studied indicates that the addition of cannabis had little to no impact on pain relief. A systematic review and meta-analysis in 2021 by Noori et al., which included eight randomized and observational studies, yielded very low-certainty evidence that cannabis use could reduce opioid consumption. One explanation for this phenomenon could be the substitution effect of cannabis for opioids, or it may reflect an opiate-sparing effect of cannabis. While numerous preclinical and animal studies have indicated a possible opioid-sparing effect, effective translation to clinical outcomes has been sought.
